The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinsons disease

Jose L. Barboza, Michael S. Okun, Baharak Moshiree

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Introduction: Parkinsons disease (PD) affects the nerves of the entire gastrointestinal (GI) tract and may result in profound gastrointestinal (GI) dysfunction leading to poor patient outcomes. Common GI disturbances in patients with PD include gastroparesis (GP), constipation and small intestinal bacterial overgrowth syndrome (SIBO). In particular, GP is difficult to treat due to the limited options available and precautions, contraindications and adverse effects associated with the approved treatments. Moreover, some commonly used medications can worsen pre-existing PD.Areas covered: Our review will focus on treatment options for GP and SIBO with motilin agonists, dopamine receptor antagonists, Ghrelin agonists muscarinic agonists, 5-HT4 receptor agonists, antibiotics, probiotics and herbal formulation such as iberogast. Constipation occurs in the majority of patients with PD and fortunately many treatments are now available. Our review is based on original papers or reviews selected from PUBMED search and Cochrane reviews.Expert opinion: Motility disorders of the GI tract are found frequently in patients with PD and treating the underlying GI disorders caused by PD with various prokinetics and laxatives is paramount in achieving improvements in patients motor function. Various prokinetics and laxatives are now available to provide some relief of the GI morbidity caused by PD leading even to better absorption of even the PD treatments.

Original languageEnglish (US)
Pages (from-to)2449-2464
Number of pages16
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number16
DOIs
StatePublished - Nov 2 2015

Keywords

  • 5-HT receptor agonists
  • autonomic nervous system dysfunction
  • azithromycin
  • constipation
  • domperidone
  • dysmotility
  • erythromycin
  • gastrointestinal
  • gastroparesis
  • iberogast
  • linaclotide
  • lubiprostone
  • mosapride
  • nizatidine
  • non-motor symptoms
  • Parkinson's disease
  • PEG
  • probiotics
  • prucalopride
  • rifaximin
  • RM-131
  • small intestinal bacterial overgrowth syndrome
  • STW5
  • TZP-101
  • TZP-102
  • ulimorelin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinsons disease'. Together they form a unique fingerprint.

Cite this